13-azaprostanoic acid has been researched along with tyrosine in 1 studies
| Studies (13-azaprostanoic acid) | Trials (13-azaprostanoic acid) | Recent Studies (post-2010) (13-azaprostanoic acid) | Studies (tyrosine) | Trials (tyrosine) | Recent Studies (post-2010) (tyrosine) |
|---|---|---|---|---|---|
| 42 | 0 | 0 | 44,273 | 846 | 8,225 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casonato, A; Deana, R; Francesconi, M; Girolami, A; Scapin, M | 1 |
1 other study(ies) available for 13-azaprostanoic acid and tyrosine
| Article | Year |
|---|---|
Adrenaline potentiates type 2B von Willebrand factor-induced activation of human platelets by enhancing both the formation and action of thromboxanes.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adrenergic alpha-Antagonists; Arachidonic Acid; Aspirin; Blood Platelets; Calcium; Drug Synergism; Epinephrine; Humans; Kinetics; Lipoxygenase; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Prostanoic Acids; Serotonin; Sympathomimetics; Thromboxanes; Tyrosine; Vasoconstrictor Agents; von Willebrand Factor; Yohimbine | 2000 |